MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
7.57
-0.18 (-2.32%)
Nov 19, 2025, 10:02 AM EST - Market open
MeiraGTx Holdings Revenue
MeiraGTx Holdings had revenue of $410.00K in the quarter ending September 30, 2025, a decrease of -96.24%. This brings the company's revenue in the last twelve months to $27.42M, up 96.83% year-over-year. In the year 2024, MeiraGTx Holdings had annual revenue of $33.28M with 137.42% growth.
Revenue (ttm)
$27.42M
Revenue Growth
+96.83%
P/S Ratio
22.60
Revenue / Employee
$71,961
Employees
381
Market Cap
609.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.28M | 19.26M | 137.42% |
| Dec 31, 2023 | 14.02M | -1.90M | -11.95% |
| Dec 31, 2022 | 15.92M | -21.78M | -57.77% |
| Dec 31, 2021 | 37.70M | 22.14M | 142.25% |
| Dec 31, 2020 | 15.56M | 2.27M | 17.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MGTX News
- 6 days ago - MeiraGTx Reports Third Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 6 days ago - MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential - Seeking Alpha
- 9 days ago - Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease - Reuters
- 9 days ago - MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology - GlobeNewsWire
- 6 weeks ago - MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress - GlobeNewsWire
- 7 weeks ago - MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital - Seeking Alpha
- 3 months ago - MeiraGTx Reports Second Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 6 months ago - MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - GlobeNewsWire